Home Your basket
• Treatment failures in ben...
   Price 10.50 €
• Utility of positron emiss...
   Price 8.50 €
• Wegener granulomatosis mi...
   Price 14.00 €
• Notes on voice and speech...
   Price 8.50 €
• Bilateral cochlear implan...
   Price 5.50 €
• Apology for the biplane c...
   Price 10.50 €
• Cephalic vein access for ...
   Price 10.50 €
• Nasal polyposis: long ter...
   Price 10.50 €
• Otosclerosis among patien...
   Price 10.50 €
• Rejuvenation of the eye: ...
   Price 10.50 €
• Dermatofibrosarcoma protu...
   Price 10.50 €
• The three-stage frontal f...
   Price 14.00 €
• Revision ossiculoplasty: ...
   Price 10.50 €
• Perceptual assessment of ...
   Price 10.50 €
• Efficacy and safety of mo...
   Price 10.50 €
• A survey of current wound...
   Price 5.50 €
• Ambulatory stapedectomy: ...
   Price 8.50 €
• Evaluation of the handica...
   Price 10.50 €
• Sentinel lymph node biops...
   Price 15.00 €
• The frontal pneumosinus d...
   Price 8.50 €
• Vertebro and cranio veino...
   Price 14.00 €
• Reverse phonation: Pathol...
   Price 8.50 €
• Otoplasty: Special attent...
   Price 8.50 €
• Cosmetic radiofrequency...
   Price 10.50 €
• Interests of multimedia s...
   Price 10.50 €
• Traditional and emerging ...
   Price 10.50 €
• A comparative acoustic st...
   Price 5.50 €
• Frontal sinus osteoma com...
   Price 5.50 €
• Adenomatoid hamartoma of ...
   Price 5.50 €
• Hearing results in stapes...
   Price 10.50 €
• Bell's palsy: treatment b...
   Price 5.50 €
• Neuroplasticity in the au...
   Price 10.50 €
• Interest of MIBI scintigr...
   Price 10.50 €
• Cowden syndrome: Otolaryn...
   Price 12.00 €
• Diagnosis and treatment o...
   Price 10.50 €
• Validation of a clinical ...
   Price 10.50 €
• Characteristics of the ma...
   Price 12.50 €
• Type III ossiculoplasty w...
   Price 5.50 €
• Usher type I syndrome in ...
   Price 10.50 €

Total Order 381.00 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 4 - 2008 o

OTONEUROLOGY

Disability in patients with Menière’s disease following the use of two different treatment modalities: Betahistine and intratympanic gentamicin


Authors : Enrique-Gonzalez A, Sánchez-Ferrándiz N, Pérez-Fernández N. (Pamplona)

Ref. : Rev Laryngol Otol Rhinol. 2008;129,4:249-254.

Article published in english
Downloadable PDF document english



Summary : Objective: The objective of this study was to assess the level of residual disability and handicap in patients with Menière’s disease (MD) that were free of new vertigo spells 2 years after having been administered treatment with either oral medication or with intratympanic gentamcin. Setting: University hospital. Tertiary medical center. Material and method: 40 patients with MD were included in this study, of which 20 were treated with oral medication (betahistine) and 20 with intratympanic gentamicin; intratympanic gentamicin was for patients considered failures for the oral medication treatment. All of them are free of new vertigo in the 16-24 month period after beginning the treatment. They were matched by age and disease duration. Disability and handicap were assessed with conventional questionnaires at the time of inclusion and 2 years after beginning oral medication or ended the intratympanic gentamicin treatment. According to the treatment two groups were created: oral medication treatment and intratympanic gentamicin treatment. Results: The amount of disability before treatment was higher in patients treated with intratympanic gentamicin than in those under oral medication; However, after treatment when no more vertigo spells takes place, this disability is significantly reduced and becomes similar for both groups of patients. In patients treated with oral medication the items reflecting the intensity of vertigo spell, the impact of vertigo in daily activities, the perception of quality of life and level of somatization do not show a significant reduction. Conclusion: The number or frequency of vertigo spells are very relevant for the process of disability and handicap of patients with MD when that is low or when oral medication is sufficient to eliminate vertigo spells. However when that number is high and the only possibility to arrest those vertigo spells is the use of intratympanic gentamicin, fear of vertigo must be considered as an associated problem for the patient.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE